Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Co-administration with Boostrix and/or Menactra in Healthy Females
NCT00369824Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Primary completion
- Nov 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (6 arms), sponsored by GSK. Primary endpoints: Anti-diphtheria Toxoid and Anti-tetanus Toxoid Antibody Concentrations, Anti-pertussis Toxoid, Anti-pertactin, and Anti-filamentous Hemagglutinin Antibody Concentrations and 1 more. Started Sep 2006; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00369824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369824.